NovoCure LimitedNVCRNASDAQ
Loading
EBITDA Margin Over TimeContracting
Percentile Rank42
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

Percentile
P42
Within normal range
vs 5Y Ago
-2.2x
Contraction
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM-20.01%-10.5%
2024-18.11%+48.0%
2023-34.84%-176.0%
2022-12.62%-75.9%
2021-7.17%-179.1%
20209.07%+137.0%
20193.83%+140.5%
2018-9.45%+42.6%
2017-16.45%+87.5%
2016-131.37%-